Li, Ying Fei http://orcid.org/0000-0002-1406-8538
Combes, Francois Pierre http://orcid.org/0000-0002-8637-7372
Hoch, Matthias
Lorenzo, Sebastien
Sy, Sherwin K. B. http://orcid.org/0000-0001-6405-9130
Ho, Yu-Yun
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases
https://doi.org/10.1007/s40262-022-01148-9
Documents that mention this clinical trial
Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases
https://doi.org/10.1007/s40262-022-01148-9
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Accepted: 29 May 2022
First Online: 28 June 2022
Change Date: 17 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40262-022-01166-7
Declarations
:
: Not applicable.
: All authors are employees of Novartis. SL, SS, YFL, Y-YH, MH, and FPC own Novartis shares. FPC also owns Simulation Plus shares.
: Not applicable.
: Not applicable.
: Not applicable.
: Anonymized patient‐level data from clinical trials may be shared by Novartis in a consortium called ClinicalStudyDataRequest.com (CSDR) in accordance with Novartis’ policy for sharing clinical trial data (ExternalRef removed).
: Not applicable.
: All the authors contributed to designing and performing the research, data analysis, and drafting and review of the manuscript. All authors read and approved the final manuscript.